| Literature DB >> 31437421 |
Daniela Caldas Teixeira1, Lilian Martins Oliveira Diniz2, Nathalia Sernizon Guimarães3, Henrique Morávia de Andrade Santos Moreira3, César Caldas Teixeira4, Roberta Maia de Castro Romanelli5.
Abstract
OBJECTIVE: The aim of this study was to systematically review the literature and answer the following central question: "What are the risk factors associated with worse clinical outcomes of pediatric bacterial meningitis patients?"Entities:
Keywords: Bacterial infection; Child; Complications; Complicações; Criança; Criança hospitalizada; Hospitalized child; Infecção bacteriana; Mortalidade; Mortality; Pediatria; Pediatrics
Mesh:
Year: 2019 PMID: 31437421 PMCID: PMC9432045 DOI: 10.1016/j.jped.2019.07.003
Source DB: PubMed Journal: J Pediatr (Rio J) ISSN: 0021-7557 Impact factor: 2.990
Figure 1Stages of the selection process for article inclusion in the systematic review.
Characteristics of included studies on risk factors associated with the outcomes of pediatric bacterial meningitis.
| Source | Location | Study | Age of cohort | Outcomes | Prevalence | Independent predictors – OR (95% CI) | ||
|---|---|---|---|---|---|---|---|---|
| 1 | 1993, Kilpi | Finland | Retrospective cohort – 1984 to 1989 | 3 months to 15 years | 286 | Death, neurologic abnormalities, and subdural effusion. | 3%/15.7%/8% | Long duration of illness before hospitalization. |
| 2 | 1995, Kaaresen | Norway, Tromso | Retrospective cohort – 1980 to 1993 | 1 month to 15 years | 92 | Death, later sequelae (persisted for more than 1 y) – hydrocephalus, mental retardation, cerebral palsy, motor deficits, ataxia, hearing impairment, seizure disorder, or focal neurological findings. | 4.3%/15.2% | Duration of symptoms >48 h – OR 9.9 (1.7–56.6), seizure before admission – OR 11.2 (1.5–84.7), admission temperature >38 °C – OR 0.1 (0.02–0.9), peripheral vasoconstriction – OR 9.4 (2.0–45.3), CSF leucocytes < 1000 × 106 – OR 4.7 (1.1–21.0). |
| 3 | 1998, Chang | Taiwan | Retrospective cohort – 1989 to 1995 | Unknown | 101 | Early fatality (first 3 days after admission). | 23% | Metabolic acidosis – OR 8.31 (2.48–27.92), poor skin perfusion – OR 28.72 (3.06–268.88), extremely low CSF leukocyte count – OR 14.63 (1.44–187.14). |
| 4 | 2002, Oostenbrink | Rotterdam, Netherlands | Case-control – 1988 to 1998 | 1 month to 15 years | 170 | Death and neurological sequelae – deafness, mild hearing loss, severe mental retardation with locomotors deficits, epilepsy, mild locomotors deficits, mild mental retardation. | 8.7%/14% | Male gender – OR 3.5 (1.2–1.01), presence of atypical convulsions – OR 5.7 (1.6–20.3), lower body temperature – OR 0.5 (0.3–0.7), |
| 5 | 2005, Farag | Alexandria, Egypt | Prospective cohort study – 2002 to 2003 | 3 month to 15 years | 310 | Death and epilepsy. | 13.9%/7.1% | WHO meningitis score 9 – OR 22.7 (18.3–69.2), CSF glucose levels, |
| 6 | 2008, Roine | Multicentric | Prospective cohort study | Unknown | 654 | Death, severe neurological sequelae, milder neurological sequelae. | 13%/8%/18% | Glasgow Coma Score – OR 3.67 (1.79–7.53). |
| 7 | 2009, Pelkonen | Luanda, Angola | Retrospective cohort - 2004 | 2 months to 12 years | 403 | Death, severe neurological sequelae at hospital discharge – blindness, quadriplegia and/or paresis, hydrocephalus requiring a shunt, severe psychomotor retardation. | 33%/25% | Impaired consciousness – OR 2.61 (1.44–4.72), severe dyspnea – OR 2.42 (1.17–5.03), seizures – OR 2.49 (1.36–4.58), delayed presentation – OR 3.73 (1.24–11.26), prolonged fever, secondary fever, prolonged altered consciousness, focal neurological signs, extra meningeal focus of infection, dehydration. |
| 8 | 2011, Vasilopoulou | Athens, Greece | Prospective cohort | 1 month to 14 years | 2477 | Acute complications – arthritis or subdural effusion; Sequelae – severe hearing loss, ventriculitis, hydrocephalus, seizure disorder (during 3 mo follow-up). | 6.8%/3.3% | Age <1 y at diagnosis – OR 18 (7.7–42.3), seizures on admission – OR 5.36 (2.63–10.90), symptoms duration >24 h – OR 2.1 (1.2–3.8), absence of hemorrhagic rash, low CSF glucose, high CSF protein, positive blood culture, |
| 9 | 2012, Bargui | Paris, France | Retrospective cohort – Jan 1995 to Dec 2004 | 1 month to 18 years | – | Death, neurologic deficit at the time of last 10 y follow-up visit – hearing loss, motor impairment, metal retardation, epilepsy, sleep disorders, migraine, psychiatric disorders. | 21%/40% | Mechanical ventilation – OR 11.54 (2.4–55.5), thrombocytopenia – OR 2.06 (1.07–6.08), earlier age at diagnosis – OR 1.01 (1.01–1.03), delay from onset of symptoms to initiation of therapy – OR 1.33 (1.05–1.70), hydrocephalus or initial head CT scan – OR 2.60 (1.12–6.04). |
| 10 | 2013, Namani | Republic of Kosovo | Retrospective cohort – Jan 1997 to Dec 2002, Jan 2009 to Dec 2010. | Up to 16 years | 354 | Sequelae persisting during the 2-3y follow up period – seizures, deafness, neuropsychological impairment, quadri/hemiparesia, amaurosis. | 10% | Age at diagnosis (infants) – OR 2.69 (1.62–4.59). |
| 11 | 2013, Theodoridou | Athens, Greece | Prospective cohort – 1974 to 2005 | 1 month to 14 years | 2477 | Sequelae – seizure disorder, severe hearing loss, ventriculitis, and hydrocephalus. | 3.3% | Treatment with gentamicin, trimethoprim/sulfamethoxazole, chloramphenicol, |
| 12 | 2013, McCormick | Blantyre, Malawi | Retrospective cohort – 1997 to 2010 | 2 months to 15 years | 784 | Death, severe sequelae. | 28.7%/26.2% | Impaired consciousness – Death OR 14.4 (9.42–22.1)/sequelae OR 3.27 (2.02–5.29), HIV seropositivity - OR 1.65 (1.2–2.26), |
| 13 | 2013, Namani | Republic of Kosovo | Prospective cohort – Jan 2009 to Dec 2010. | 1 month to 16 years | 77 | Neurological complications – subdural effusion, recurrent seizures, hemiparesis, intracerebral hemorrhage, cerebritis, facial nerve palsy, hydrocephalus, subdural hematoma, cerebral abscess, subdural empyema, and purulent ventriculitis. | 43% | Seizures prior to admission, altered mental status or focal neurological deficits at the time of admission, increased protein levels, age <12 mo – RR 2.69 (1.62–4.59). |
| 14 | 2014, Roine | Luanda, Angola | Post ROC descriptive analysis – Jul 2005 to Jun 2008 | 2 months to 12 years | 553 | Risk of dying very quickly (0–4 h), quickly (4–8 h), or after long periods. | 37% | Short disease history, shock, hypoglycemia – OR 4.47 (1.72–11.6), poor cerebrospinal fluid white cell response – OR 4.46 (1.72–11.5). |
| 15 | 2015, Corrêa | Pernambuco Brazil | Retrospective case-control study – Jan 2004 to Dec 2008. | 1 month to 14 year | 289 | Acute symptomatic seizure | 23% | Impaired mental status at admission – OR 3.47 (1.66–7.26), |
| 16 | 2015, Olson | Guatemala | Prospective cohort – 2000 to 2007 | 0 to 59 months | 383 | Death, surviving with major morbidity – hydrocephaly, convulsions, cerebral stroke, cranial nerve paralysis. | 23.7%/27.3% | Seizure – OR 101.5, CSF glucose < 20 mg/dL – OR 5.3, symptom duration > 3 days – OR 3.7, coma – OR 6.3. |
| 17 | 2016, Wee | Singapore | Retrospective cohort – 1998 to 2013 | 3 days to 15 years | 121 | ICU admission, residual sequelae 5 y after meningitis – sensorineural hearing loss, cortical blindness, developmental delay or learning difficulties, cerebral palsy or other neuromotor deficits, hydrocephalus, epilepsy, feeding difficulty requiring assisted feeding. | 44% |
CT, computed tomography; CSF; cerebral spinal fluid; ICU; intensive care unit.
Summary of studies considering risk factors associated with the outcome of pediatric bacterial meningitis.
| Quality assessment | Quality | ||||||
|---|---|---|---|---|---|---|---|
| Studies | Study design | Methodological bias | Inconsistency | Indirect evidence | Imprecision | Publication bias | |
| 17 | 8 prospective cohort | No severe limitation | Severe inconsistency | No important indirect evidence | Severe imprecision | No important publication bias | Very low |
| 6 retrospective cohort | |||||||
| 2 case-control | |||||||
| 1 cross-sectional | |||||||
All the studies were observational, presenting a greater risk of bias.
Given that these were not meta-analyses, I2 was not calculated.
Although the studies presented methodological differences between themselves and based on the population, exposition, comparison, outcome, and study type (PECOS) analysis of the review, no important indirect evidence was observed.
The absolute effect (difference between the exposed and non-exposed groups) was not calculated because the studies did not present effect measures.
Despite few studies found, an extensive search was conducted in several databases and the references of the studies. There was no language restriction.
The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) quality of evidence in the review was very low, since it had already begun with a low level of evidence, given that only observational studies were found.